Nuclear Pharmacy Market By Type-
Nuclear Pharmacy Market By Application-
Nuclear Pharmacy Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Nuclear Pharmacy Market Snapshot
Chapter 4. Global Nuclear Pharmacy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis of Metaverse Industry
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. COVID-19 Impact on Metaverse Industry
Chapter 5. Market Segmentation 1: By Type Estimates & Trend Analysis
5.1. By Type & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Type:
5.2.1. Diagnostic Nuclear Medicine
5.2.1.1. SPECT Radiopharmaceuticals
5.2.1.1.1. Tc-99m
5.2.1.1.2. I-123
5.2.1.1.3. Tl-201
5.2.1.1.4. Ga-67
5.2.1.1.5. Other SPECT Isotopes
5.2.1.2. PET Radiopharmaceuticals
5.2.1.2.1. F-18
5.2.1.2.2. Rb-82
5.2.1.2.3. Other PET Isotopes
5.2.2. Therapeutic Nuclear Medicine
5.2.2.1. Alpha Emitters
5.2.2.1.1. Ra-223
5.2.2.2. Beta Emitters
5.2.2.2.1. I-131
5.2.2.2.2. Y-90
5.2.2.2.3. Sm-153
5.2.2.2.4. Lu-177
5.2.2.2.5. Re-186
5.2.2.2.6. Other Beta Emitters
5.2.3. Brachytherapy Isotopes
5.2.3.1. I-125
5.2.3.2. Ir-192
5.2.3.3. Pd-103
5.2.3.4. Cs-131
5.2.3.5. Other Brachytherapy Isotopes
Chapter 6. Market Segmentation 2: By Application Estimates & Trend Analysis
6.1. By Type & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Application:
6.2.1. Diagnostic Applications
6.2.1.1. SPECT Applications
6.2.1.1.1. Cardiology
6.2.1.1.2. Bone Scans
6.2.1.1.3. Thyroid Applications
6.2.1.1.4. Pulmonary Scans
6.2.1.1.5. Other SPECT Applications
6.2.1.2. PET Applications
6.2.1.2.1. Oncology
6.2.1.2.2. Cardiology
6.2.1.2.3. Neurology
6.2.1.2.4. Other PET Applications
6.2.2. Therapeutic Applications
6.2.2.1. Thyroid Indications
6.2.2.2. Bone Metastasis
6.2.2.3. Lymphoma
6.2.2.4. Endocrine Tumors
6.2.2.5. Other Indications
Chapter 7. Nuclear Pharmacy Market Segmentation 4: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Nuclear Pharmacy Market revenue (US$ Million) estimates and forecasts By Type, 2021-2034
7.1.2. North America Nuclear Pharmacy Market revenue (US$ Million) estimates and forecasts By Application, 2021-2034
7.1.3. North America Nuclear Pharmacy Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
7.1.3.1. U.S.
7.1.3.2. Canada
7.2. Europe
7.2.1. Europe Nuclear Pharmacy Market revenue (US$ Million) by By Type, 2021-2034
7.2.2. Europe Nuclear Pharmacy Market revenue (US$ Million) estimates and forecasts By Application, 2021-2034
7.2.3. Europe Nuclear Pharmacy Market revenue (US$ Million) by country, 2021-2034
7.2.3.1. Germany
7.2.3.2. Poland
7.2.3.3. France
7.2.3.4. Italy
7.2.3.5. Spain
7.2.3.6. UK
7.2.3.7. Rest of Europe
7.3. Asia Pacific
7.3.1. Asia Pacific Nuclear Pharmacy Market revenue (US$ Million) by By Type, 2021-2034
7.3.2. Asia Pacific Nuclear Pharmacy Market revenue (US$ Million) estimates and forecasts By Application, 2021-2034
7.3.3. Asia Pacific Nuclear Pharmacy Market revenue (US$ Million) by country, 2021-2034
7.3.3.1. China
7.3.3.2. India
7.3.3.3. Japan
7.3.3.4. Australia
7.3.3.5. Rest of Asia Pacific
7.4. Latin America
7.4.1. Latin America Nuclear Pharmacy Market revenue (US$ Million) by By Type, 2021-2034
7.4.2. Latin America Nuclear Pharmacy Market revenue (US$ Million) estimates and forecasts By Application, 2021-2034
7.4.3. Latin America Nuclear Pharmacy Market revenue (US$ Million) by country, (US$ Million) 2021-2034
7.4.3.1. Brazil
7.4.3.2. Rest of Latin America
7.5. Middle East & Africa
7.5.1. Middle East & Africa Nuclear Pharmacy Market revenue (US$ Million) by By Type, 2021-2034
7.5.2. Middle East & Africa Nuclear Pharmacy Market revenue (US$ Million) estimates and forecasts By Application, 2021-2034
7.5.3. Middle East & Africa Nuclear Pharmacy Market revenue (US$ Million) by country, (US$ Million) 2021-2034
7.5.3.1. South Africa
7.5.3.2. GCC Countries
7.5.3.3. Rest of MEA
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1 GE HealthCare
8.2.2 Cardinal Health
8.2.3 Curium
8.2.4 Bayer AG
8.2.5 Lantheus Holdings, Inc.
8.2.6 Bracco Imaging S.p.A.
8.2.7 PharmaLogic Holdings Corp.
8.2.8 Eczacibasi-Monrol Nuclear Products
8.2.9 NTP Radioisotopes SOC Ltd
8.2.10 Nordion Inc.
8.2.11 Novartis (Advanced Accelerator Application)
8.2.12 NorthStar Medical Radioisotopes
8.2.13 Eckert & Ziegler
8.2.14 Isotope JSC
8.2.15 Siemens Healthineers
8.2.16 Jubilant DraxImage,Inc.
8.2.17 Telix Pharmaceuticals Limited
8.2.18 Mallinckrodt Pharmaceuticals
8.2.19 Bracco
8.2.20 IBA Worldwide
8.2.21 Other Prominent Players
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.